ARE — Alexandria Real Estate Equities, Inc.

Market sentiment is cautious-neutral. ARE is up ~10% year-to-date after a ~33% trailing-twelve-month decline, and Wall Street's consensus is Hold with price targets clustered between $50 and $60. The Q2 print was a two-sided tape: FFO of $1.73 beat estimates, but GAAP net income was depressed by impairments, same-property NOI fell ~10.6% on a GAAP basis, and management's FFO guidance midpoint of $6.40 did not signal a confident near-term rebound.

FMP's quarterly revenue path is choppy—roughly $776M in Q3 2024, $671M in Q1 2026, then $796M in Q2 2026 (the company's own release cited a lower revenue figure, so absolute top-line comparability is messy). The clearer trend is margin and earnings deterioration: operating income fell from about $205M in Q3 2024 to $25M in Q2 2026, and operating margin compressed from roughly 26% to about 3%. GAAP net income was negative in six of the last twelve quarters, including a $1.08B loss in Q4 2025 largely from impairments. Operating cash flow also softened: $337M in Q2 2026 versus $460M a year earlier. This is a deteriorating trajectory, not a one-quarter blip, although adjusted FFO remains positive and the leasing volume rebound in Q2 offers a possible early stabilization signal.

As of 2026-08-27, ARE looks cheap on headline multiples: trailing P/E is negative at -9.4x, price-to-sales is 3.08x versus a 5-year average of 8.12x, and price-to-book is 0.63x. The more relevant REIT framework is FFO: at $52.28 against the 2026 FFO guidance midpoint of $6.40, the stock trades at roughly 8.2x FFO. That is a historically low multiple for a high-quality lab REIT, but the discount is rationalized by falling occupancy, negative same-property NOI growth, and elevated interest rates. So: cheap versus its own history, but not cheap enough to ignore the weakened forward earnings power.

Trailing GAAP EPS is -$4.80, so a conventional P/E on trailing earnings is meaningless here; the market is pricing ARE on FFO. The current price implies the market expects FFO to stay around $6.40 or drift lower. If management holds guidance and life-science leasing continues to recover, 8.2x FFO is likely too low and the stock could re-rate toward the $55-$60 analyst target zone. If FFO falls toward $5.50-$6.00 as supply pressures persist, the current multiple is not as compelling. The playbook is to wait for occupancy and same-property NOI to stabilize before treating the low FFO multiple as a value signal.

As of 2026-08-27, RSI is 55.2, which is neutral rather than overbought or oversold. Price is 4.1% above the 20-day SMA, 3.2% above the 50-day SMA, and 4.2% above the 200-day SMA. That reflects a modest short-term uptrend after a major drawdown from $88.24 to $39.41, but the stock is mid-range, not at a low-risk technical entry. A pullback toward the 50-day SMA or a volume-confirmed break above the high-$50s would be more informative than chasing this 4% SMA breakout.

• Elevated interest rates and high cost of capital; ARE's August 2026 $1B junior subordinated notes offering highlights the ongoing financing drag.
• Structural life-science supply glut across Greater Boston, San Francisco, and San Diego continues to pressure rents and occupancy.
• Biotech funding and large pharma R&D spending cycles dictate demand for new lab and megacampus space.
• REIT sector-wide discount and lingering office/lab asset-class stigma keep multiples below historical norms.
• A potential Fed rate-cutting path in late 2026/2027 would lower cap rates and support asset values, but timing remains uncertain.

• Q3 2026 earnings on October 26-27, 2026, where investors will watch occupancy, leasing volume, and any initial 2027 FFO guidance.
• Major new or expansion leases with pharma tenants—such as the completed Bristol-Myers Squibb hub—that stabilize occupancy above 87%.
• Declining long-term interest rates or tighter credit spreads, which would reduce the cost of capital and support net-asset-value recovery.
• Asset sales or refinancings that demonstrate liquidity and reduce leverage concerns.

• Life-science supply glut persists, pushing occupancy below 86.9% and driving further rent and same-property NOI declines.
• High interest rates and capital-market friction; the current ratio is 0.11, and cash of $470M against $4.6B of current liabilities highlights reliance on revolver and debt markets, although the $3.6B liquidity cushion provides a buffer.
• FFO could weaken further, pressuring the dividend despite the current payout ratio of roughly 54% of FFO.
• Further real estate impairments and GAAP write-downs could keep eroding book value and investor confidence.

ARE is a high-quality life-science REIT in a genuine cyclical downturn, not obviously a broken franchise. But the fundamentals are still moving the wrong way—occupancy down, same-property NOI down sharply, and operating margins compressed—and the cheap multiple partly reflects that. As of 2026-08-27, I would not chase the recent strength; a more compelling entry would be after leasing and occupancy stabilize or if the stock returns toward the low-to-mid $40s.

I used a REIT-appropriate P/FFO approach: 2026 FFO guidance midpoint of $6.40 times 8.5x. The 8.5x multiple is below what ARE has historically commanded in healthier markets, reflecting occupancy below 87%, negative same-store NOI, and heavy supply, but above the current ~8.2x because the balance sheet is manageable, the dividend is covered, and the assets are high-quality life-science campuses.